Edition:
United Kingdom

People: Dermira Inc (DERM.OQ)

DERM.OQ on NASDAQ Stock Exchange Global Select Market

8.38USD
19 Jul 2019
Change (% chg)

$-0.04 (-0.48%)
Prev Close
$8.42
Open
$8.39
Day's High
$8.47
Day's Low
$8.23
Volume
130,160
Avg. Vol
436,431
52-wk High
$15.47
52-wk Low
$6.00

Ringo, William 

Mr. William R. Ringo, Jr. is Independent Director of the Company. Mr. Ringo has been a director of our company since July 2014. Mr. Ringo has served as a senior advisor to Barclays Healthcare Group, an investment banking division, and as a strategic advisor to Sofinnova Ventures, a venture capital firm, since June 2010. From April 2008 until his retirement in April 2010, Mr. Ringo was Senior Vice President of Business Development and Corporate Strategy of Pfizer Inc., a pharmaceutical company. Prior to joining Pfizer, he served as an executive in residence at Warburg Pincus and Sofinnova Ventures. From August 2004 to April 2006, Mr. Ringo was President and Chief Executive Officer of Abgenix, Inc., a biotechnology firm. Previously, Mr. Ringo held a number of senior positions in the oncology and critical care, internal medicine, infection disease and sales and marketing divisions at Eli Lilly from 1973 until 2001. Mr. Ringo is currently a member of the boards of directors of Assembly Biosciences, Inc., a publicly-traded biotechnology company, Five Prime Therapeutics, a publicly-traded biotechnology company, and Immune Design Corp., an immunotherapy company recently acquired by Merck. Mr. Ringo previously served as a member of the boards of directors of Onyx Pharmaceuticals from 2011 to October 2013, Mirati Therapeutics, Inc. from March 2014 to December 2016 and Sangamo Biosciences, Inc. from 2010 to January 2018. Mr. Ringo received a B.S. in industrial management and an M.B.A. from the University of Dayton. Our board of directors believes that Mr. Ringo’s extensive senior executive experience and service on the boards of directors of a number of private and public biotechnology and pharmaceutical companies in the life sciences industry qualify him to serve on our board of directors.

Basic Compensation

Total Annual Compensation, USD 96,375
Restricted Stock Award, USD 29,850
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 126,225

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Thomas Wiggans

4,371,180

Luis Pena

2,519,500

Andrew Guggenhime

2,360,030

Christopher Horan

2,358,110

Christopher Griffith

833,154

Lori Lyons-Williams

2,704,630
As Of  31 Dec 2018